Author:
Tang Jun,Han Tianci,Tong Wei,Zhao Jian,Wang Wei
Abstract
AbstractN6-methyladenosine (m6A) modification has been convincingly identified to be a critical regulator in human cancer. However, the contribution of m6A to NSCLC gefitinib resistance is still largely unknown. Here, we screened and identified that m6A methyltransferase KIAA1429 was highly expressed in gefitinib-resistant NSCLC cells (PC9-GR), tissues, and closely related to unfavorable survival. Functionally, KIAA1429 accelerated the gefitinib resistance of NSCLC in vitro. Depletion of KIAA1429 repressed the tumor growth of PC9-GR cells in vivo. Mechanistically, KIAA1429 enhanced the mRNA stability of HOXA1 through targeting its 3′-untranslated regions (3′-UTR). Overall, our findings indicate that KIAA1429 plays essential oncogenic roles in NSCLC gefitinib resistance, which may provide a feasible therapeutic target for NSCLC.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference25 articles.
1. Chen, H., Fu, Q. & Sun, K. Efficacy and prognosis analysis of surgical treatment for bilateral synchronous multiple primary non-small cell lung cancer. Rev. da Associacao Med. Brasileira 24, 2245–2252 (1992).
2. Jiang, S. S. et al. Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review. BMC Pulm. Med. 19, 262 (2019).
3. Ma, X., Liang, A. L. & Liu, Y. J. Research progress on the relationship between lung cancer drug-resistance and microRNAs. J. Cancer 10, 6865–6875 (2019).
4. Nishino, M., Soejima, K. & Mitsudomi, T. Brain metastases in oncogene-driven non-small cell lung cancer. Transl. Lung Cancer Res. 8, S298–S307 (2019).
5. Iwahori, K. et al. Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma: case report. Neurochirurgie 66, 477–483 (2020).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献